Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

Monika Fischer, Dina Kao, Colleen Kelly, Aishwarya Kuchipudi, Syed Mohammed Jafri, Mark Blumenkehl, Douglas Rex, Mark Mellow, Nirmal Kaur, Harry Sokol, Gwen Cook, Matthew J. Hamilton, Emmalee Phelps, Brian Sipe, Huiping Xu, Jessica R. Allegretti

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: New treatments are needed as Clostridium difficile infection (CDI) is becoming increasingly formidable. Fecal microbiota transplantation (FMT) has a 90% success rate in the treatment of recurrent CDI. However, evidence regarding its safety, efficacy, and effect on disease activity in patients with inflammatory bowel disease (IBD) is lacking. Methods: This cohort study used data from 8 national and international academic centers. Patients with established IBD who underwent FMT for recurrent CDI were followed for a minimum of 3 months. The primary outcome was CDI recurrence at 3 months after FMT. The secondary outcomes were (1) IBD activity and severity at 3 months based on the judgment of the treating physician, endoscopic findings, and clinical disease activity scores; and (2) safety. Results: Sixty-seven patients were included in the analysis. Thirty-five (52%) had Crohn's disease, 31 (46%) ulcerative colitis, and one indeterminate colitis with 43 (64%) patients on an immunosuppressive agent at the time of FMT. The initial FMT was successful in 53 (79%) patients. After the FMT, IBD disease activity was reported as improved in 25 (37%), no change in 20 (30%), and worse in 9 (13%) patients. Serious adverse events included colectomy (1.4%), hospitalization for CDI (2.9%), hospitalization for IBD flare (2.9%), small bowel obstruction (1.4%), CMV colitis (1.4%), and pancreatitis (1.4%). Discussion: The overall CDI cure rates were high, with a large percentage of patients experiencing clinical improvement of their IBD after FMT. A minority of patients developed an IBD flare. No severe adverse events directly attributable to FMT were found in this largest reported series of recurrent or refractory CDI patients with concurrent IBD.

Original languageEnglish (US)
Pages (from-to)2402-2409
Number of pages8
JournalInflammatory Bowel Diseases
Volume22
Issue number10
DOIs
StatePublished - Aug 26 2016

Fingerprint

Clostridium Infections
Clostridium difficile
Inflammatory Bowel Diseases
Colitis
Crohn Disease
Hospitalization
Safety
Fecal Microbiota Transplantation
Colectomy
Immunosuppressive Agents
Ulcerative Colitis
Pancreatitis
Cohort Studies
Physicians
Recurrence

Keywords

  • Clostridium difficile
  • Crohn's disease
  • fecal microbiota transplantation
  • FMT
  • IBD
  • inflammatory bowel disease
  • pseudomembranous colitis
  • ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. / Fischer, Monika; Kao, Dina; Kelly, Colleen; Kuchipudi, Aishwarya; Jafri, Syed Mohammed; Blumenkehl, Mark; Rex, Douglas; Mellow, Mark; Kaur, Nirmal; Sokol, Harry; Cook, Gwen; Hamilton, Matthew J.; Phelps, Emmalee; Sipe, Brian; Xu, Huiping; Allegretti, Jessica R.

In: Inflammatory Bowel Diseases, Vol. 22, No. 10, 26.08.2016, p. 2402-2409.

Research output: Contribution to journalArticle

Fischer, M, Kao, D, Kelly, C, Kuchipudi, A, Jafri, SM, Blumenkehl, M, Rex, D, Mellow, M, Kaur, N, Sokol, H, Cook, G, Hamilton, MJ, Phelps, E, Sipe, B, Xu, H & Allegretti, JR 2016, 'Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease', Inflammatory Bowel Diseases, vol. 22, no. 10, pp. 2402-2409. https://doi.org/10.1097/MIB.0000000000000908
Fischer, Monika ; Kao, Dina ; Kelly, Colleen ; Kuchipudi, Aishwarya ; Jafri, Syed Mohammed ; Blumenkehl, Mark ; Rex, Douglas ; Mellow, Mark ; Kaur, Nirmal ; Sokol, Harry ; Cook, Gwen ; Hamilton, Matthew J. ; Phelps, Emmalee ; Sipe, Brian ; Xu, Huiping ; Allegretti, Jessica R. / Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. In: Inflammatory Bowel Diseases. 2016 ; Vol. 22, No. 10. pp. 2402-2409.
@article{a09e907afa1942adbdfab8afabf0dddc,
title = "Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease",
abstract = "Background: New treatments are needed as Clostridium difficile infection (CDI) is becoming increasingly formidable. Fecal microbiota transplantation (FMT) has a 90{\%} success rate in the treatment of recurrent CDI. However, evidence regarding its safety, efficacy, and effect on disease activity in patients with inflammatory bowel disease (IBD) is lacking. Methods: This cohort study used data from 8 national and international academic centers. Patients with established IBD who underwent FMT for recurrent CDI were followed for a minimum of 3 months. The primary outcome was CDI recurrence at 3 months after FMT. The secondary outcomes were (1) IBD activity and severity at 3 months based on the judgment of the treating physician, endoscopic findings, and clinical disease activity scores; and (2) safety. Results: Sixty-seven patients were included in the analysis. Thirty-five (52{\%}) had Crohn's disease, 31 (46{\%}) ulcerative colitis, and one indeterminate colitis with 43 (64{\%}) patients on an immunosuppressive agent at the time of FMT. The initial FMT was successful in 53 (79{\%}) patients. After the FMT, IBD disease activity was reported as improved in 25 (37{\%}), no change in 20 (30{\%}), and worse in 9 (13{\%}) patients. Serious adverse events included colectomy (1.4{\%}), hospitalization for CDI (2.9{\%}), hospitalization for IBD flare (2.9{\%}), small bowel obstruction (1.4{\%}), CMV colitis (1.4{\%}), and pancreatitis (1.4{\%}). Discussion: The overall CDI cure rates were high, with a large percentage of patients experiencing clinical improvement of their IBD after FMT. A minority of patients developed an IBD flare. No severe adverse events directly attributable to FMT were found in this largest reported series of recurrent or refractory CDI patients with concurrent IBD.",
keywords = "Clostridium difficile, Crohn's disease, fecal microbiota transplantation, FMT, IBD, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis",
author = "Monika Fischer and Dina Kao and Colleen Kelly and Aishwarya Kuchipudi and Jafri, {Syed Mohammed} and Mark Blumenkehl and Douglas Rex and Mark Mellow and Nirmal Kaur and Harry Sokol and Gwen Cook and Hamilton, {Matthew J.} and Emmalee Phelps and Brian Sipe and Huiping Xu and Allegretti, {Jessica R.}",
year = "2016",
month = "8",
day = "26",
doi = "10.1097/MIB.0000000000000908",
language = "English (US)",
volume = "22",
pages = "2402--2409",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease

AU - Fischer, Monika

AU - Kao, Dina

AU - Kelly, Colleen

AU - Kuchipudi, Aishwarya

AU - Jafri, Syed Mohammed

AU - Blumenkehl, Mark

AU - Rex, Douglas

AU - Mellow, Mark

AU - Kaur, Nirmal

AU - Sokol, Harry

AU - Cook, Gwen

AU - Hamilton, Matthew J.

AU - Phelps, Emmalee

AU - Sipe, Brian

AU - Xu, Huiping

AU - Allegretti, Jessica R.

PY - 2016/8/26

Y1 - 2016/8/26

N2 - Background: New treatments are needed as Clostridium difficile infection (CDI) is becoming increasingly formidable. Fecal microbiota transplantation (FMT) has a 90% success rate in the treatment of recurrent CDI. However, evidence regarding its safety, efficacy, and effect on disease activity in patients with inflammatory bowel disease (IBD) is lacking. Methods: This cohort study used data from 8 national and international academic centers. Patients with established IBD who underwent FMT for recurrent CDI were followed for a minimum of 3 months. The primary outcome was CDI recurrence at 3 months after FMT. The secondary outcomes were (1) IBD activity and severity at 3 months based on the judgment of the treating physician, endoscopic findings, and clinical disease activity scores; and (2) safety. Results: Sixty-seven patients were included in the analysis. Thirty-five (52%) had Crohn's disease, 31 (46%) ulcerative colitis, and one indeterminate colitis with 43 (64%) patients on an immunosuppressive agent at the time of FMT. The initial FMT was successful in 53 (79%) patients. After the FMT, IBD disease activity was reported as improved in 25 (37%), no change in 20 (30%), and worse in 9 (13%) patients. Serious adverse events included colectomy (1.4%), hospitalization for CDI (2.9%), hospitalization for IBD flare (2.9%), small bowel obstruction (1.4%), CMV colitis (1.4%), and pancreatitis (1.4%). Discussion: The overall CDI cure rates were high, with a large percentage of patients experiencing clinical improvement of their IBD after FMT. A minority of patients developed an IBD flare. No severe adverse events directly attributable to FMT were found in this largest reported series of recurrent or refractory CDI patients with concurrent IBD.

AB - Background: New treatments are needed as Clostridium difficile infection (CDI) is becoming increasingly formidable. Fecal microbiota transplantation (FMT) has a 90% success rate in the treatment of recurrent CDI. However, evidence regarding its safety, efficacy, and effect on disease activity in patients with inflammatory bowel disease (IBD) is lacking. Methods: This cohort study used data from 8 national and international academic centers. Patients with established IBD who underwent FMT for recurrent CDI were followed for a minimum of 3 months. The primary outcome was CDI recurrence at 3 months after FMT. The secondary outcomes were (1) IBD activity and severity at 3 months based on the judgment of the treating physician, endoscopic findings, and clinical disease activity scores; and (2) safety. Results: Sixty-seven patients were included in the analysis. Thirty-five (52%) had Crohn's disease, 31 (46%) ulcerative colitis, and one indeterminate colitis with 43 (64%) patients on an immunosuppressive agent at the time of FMT. The initial FMT was successful in 53 (79%) patients. After the FMT, IBD disease activity was reported as improved in 25 (37%), no change in 20 (30%), and worse in 9 (13%) patients. Serious adverse events included colectomy (1.4%), hospitalization for CDI (2.9%), hospitalization for IBD flare (2.9%), small bowel obstruction (1.4%), CMV colitis (1.4%), and pancreatitis (1.4%). Discussion: The overall CDI cure rates were high, with a large percentage of patients experiencing clinical improvement of their IBD after FMT. A minority of patients developed an IBD flare. No severe adverse events directly attributable to FMT were found in this largest reported series of recurrent or refractory CDI patients with concurrent IBD.

KW - Clostridium difficile

KW - Crohn's disease

KW - fecal microbiota transplantation

KW - FMT

KW - IBD

KW - inflammatory bowel disease

KW - pseudomembranous colitis

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84988663720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988663720&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000908

DO - 10.1097/MIB.0000000000000908

M3 - Article

C2 - 27580384

AN - SCOPUS:84988663720

VL - 22

SP - 2402

EP - 2409

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -